Aytu BioPharma (NASDAQ:AYTU) Shares Cross Below Fifty Day Moving Average – What’s Next?

Aytu BioPharma, Inc. (NASDAQ:AYTU) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.51 and traded as low as $1.20. Aytu BioPharma shares last traded at $1.20, with a volume of 21,489 shares traded.

Aytu BioPharma Stock Down 1.2 %

The company has a current ratio of 0.98, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. The stock’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $1.82. The firm has a market capitalization of $7.43 million, a P/E ratio of -0.83 and a beta of -1.63.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.28) EPS for the quarter. Aytu BioPharma had a negative return on equity of 19.30% and a negative net margin of 7.62%.

Institutional Trading of Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC grew its stake in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 500,958 shares of the company’s stock after acquiring an additional 28,489 shares during the quarter. Aytu BioPharma comprises approximately 0.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th biggest position. Stonepine Capital Management LLC owned approximately 8.15% of Aytu BioPharma worth $1,177,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 33.49% of the stock is owned by institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.